Robuta

https://www.benzinga.com/news/earnings/20/06/16396825/12-stocks-moving-in-thursdays-after-hours-session 12 Stocks Moving In Thursday's After-Hours Session - Altimmune (NASDAQ:ALT), Bank of America... Jun 25, 2020 - Gainers: CalAmp (NASDAQ: CAMP) shares are trading higher after the company reported better-than-expected Q1 EPS and sales results. https://capital.com/en-au/markets/shares/altimmune-inc-share-price-1 Altimmune, Inc. (ALT) Stock Price Quote Today & Current Price Chart | Capital.com Australia stock price quote https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-altimmune-inc---alt-302521643.html INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. -... /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT). Such investors... on behalf of https://www.fiercebiotech.com/keyword/altimmune Altimmune | Fierce Biotech altimmunefiercebiotech https://www.biospace.com/altimmune-presents-data-on-the-effect-of-pemvidutide-on-cardioinflammatory-lipids-during-oral-presentation-at-american-diabetes-association-s-84th-annual-scientific-sessions Altimmune Presents Data on the Effect of Pemvidutide on Cardioinflammatory Lipids during Oral... Jun 24, 2024 - Altimmune, Inc., a clinical-stage biopharmaceutical company, presented data on the effect of pemvidutide, its GLP-1/glucagon dual receptor agonist candidate in... data onthe effect https://www.fxempire.com/stocks/alt/history Altimmune, Inc. Common Stock (ALT) Stock Price History | FXEmpire Get in-depth historical insights into (ALT) Altimmune, Inc. Common Stock's stock performance. With data on prices, highs, lows, and change percentages, our... common stockprice historyaltimmuneincfxempire https://www.macrotrends.net/stocks/charts/ALT/altimmune/net-income Altimmune Net Income 2012-2025 | ALT | MacroTrends Altimmune net income from 2012 to 2025. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been... net incomealtimmune20122025macrotrends https://www.fool.com/investing/2021/03/20/is-altimmune-a-buy/ Is Altimmune a Buy? | The Motley Fool Mar 20, 2021 - If you're thinking of investing in this spectacular coronavirus growth stock, now may be too late. buy thealtimmunemotleyfool https://capital.com/de-de/markets/shares/altimmune-inc-aktienkurs-1 Altimmune, Inc. (ALT) Aktie: Aktienkurs & Chart | Jetzt traden | Capital.com Deutschland Altimmune, Inc. (ticker: ALT) Echtzeit-Aktienwert, Investment, historische Daten, Rating und Finanzmarktinformationen bei Capital.com. jetzt tradenaltimmuneincaktie https://www.biospace.com/altimmune-to-report-second-quarter-2024-financial-results-and-provide-business-update-on-august-8-2024 Altimmune to Report Second Quarter 2024 Financial Results and Provide Business Update on August 8,... https://www.fxempire.com/stocks/alt/earnings Altimmune, Inc. Common Stock (ALT) Earnings Reports & Dates | FXEmpire Dive into Altimmune, Inc. Common Stock financial stats - earnings and revenue, analyze past reports, compare to industry peers' performance, and stay informed... common stockearnings reportsaltimmuneincdates https://www.globenewswire.com/news-release/2020/06/01/2041361/0/en/Altimmune-Launches-Clinical-Trial-of-T-COVIDTM-an-Investigational-Intranasal-Immune-Modulator-for-the-Treatment-of-Patients-with-Early-COVID-19.html Altimmune Launches Clinical Trial of T-COVIDTM, an Clearance of IND application received from the U.S. FDAPlanned Phase 1/2 outpatient clinical trial will focus on patients with early SARS-CoV-2 infection... clinical trialaltimmunelaunches https://www.annualreports.com/Company/altimmune-inc Altimmune, Inc. - AnnualReports.com altimmuneincannualreports https://www.prnewswire.com/news-releases/alt-investor-alert-bronstein-gewirtz--grossman-llc-announces-that-altimmune-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit-302523614.html ALT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Altimmune, Inc. Investors with... https://www.prnewswire.com/news-releases/pharmathene-and-altimmune-announce-merger-to-create-immunotherapeutics-company-targeting-infectious-diseases-300393398.html PharmAthene and Altimmune Announce Merger to Create Immunotherapeutics Company Targeting Infectious... /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP) and Altimmune, Inc., a privately-held immunotherapeutics company targeting infectious diseases, announced... to createaltimmuneannouncemerger https://www.home.saxo/da-dk/markets/stocks/alt-xnas Altimmune Inc. aktie | Saxo Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. altimmuneincaktiesaxo https://www.prnewswire.com/news-releases/shareholders-that-lost-money-on-altimmune-incalt-urged-to-join-class-action--contact-levi--korsinsky-to-learn-more-302567857.html Shareholders that lost money on Altimmune, Inc.(ALT) Urged to Join Class Action - Contact Levi &... https://www.fool.com/investing/2020/12/14/why-altimmune-stock-is-soaring-today/ Why Altimmune Stock Is Soaring Today | The Motley Fool Dec 14, 2020 - Investors are excited about an analyst's bullish opinion about the biotech stock. altimmunestocksoaringtodaymotley https://investingnews.com/company-news/altimmune-presentation-heptcell-phase-one-results-international-liver-congress/ Altimmune Announces Presentation of HepTcell Phase 1 Results at The International Liver Congress |... Jan 3, 2026 - Altimmune (Nasdaq:ALT), a clinical-stage immunotherapeutics company, today announced results of its recently completed HepTcell Phase 1 clinical trial will be... https://capital.com/de-int/markets/shares/altimmune-inc-aktienkurs-1 Altimmune, Inc. (ALT) Aktie: Aktienkurs & Chart | Jetzt traden | Capital.com Altimmune, Inc. (ticker: ALT) Echtzeit-Aktienwert, Investment, historische Daten, Rating und Finanzmarktinformationen bei Capital.com. jetzt tradenaltimmuneincaktiechart https://www.fool.com/earnings/call-transcripts/2021/08/11/altimmune-inc-alt-q2-2021-earnings-call-transcript/ ALTIMMUNE INC (ALT) Q2 2021 Earnings Call Transcript | The Motley Fool Aug 12, 2021 - ALT earnings call for the period ending June 30, 2021. earnings call transcriptaltimmuneincq22021 https://capital.com/nl-nl/markets/shares/altimmune-inc-aandeelprijs-1 Altimmune, Inc. (ALT) Koers En Grafiek | Handel Nu | Capital.com handel nualtimmuneinckoersen https://www.benzinga.com/insights/news/24/04/38078897/if-you-invested-100-in-this-stock-5-years-ago-you-would-have-300-today If You Invested $100 In This Stock 5 Years Ago, You Would Have $300 Today - Altimmune (NASDAQ:ALT)...